Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

News Focus

LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News AC Immune SA ACIU

Healthcare Biotechnology

AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small... see more

Add To Watchlist

Recent & Breaking News (NDAQ:ACIU)

AC Immune Receives Second Milestone and New Milestone to Increase the Potential Deal Value of Lilly Morphomer(TM) Tau Partnership

GlobeNewswire March 23, 2020

Internationally Renowned Neurologist Dr. Juan Fortea Joins AC Immune's Clinical Advisory Board

GlobeNewswire March 20, 2020

AC Immune to Present New Data Demonstrating the Depth of its Neurodegenerative Programs at the Upcoming Advances in Alzheimer's and Parkinson's Therapies Focus Meeting

GlobeNewswire March 5, 2020

AC Immune to Present at Jefferies 2019 London Healthcare Conference

GlobeNewswire November 14, 2019

AC Immune Q3 2019 Financial Results and Business Update

GlobeNewswire November 13, 2019

AC Immune Hosts Key Opinion Leader Event: 'Untangling' Tau Pathology to Treat Alzheimer's and Neurodegenerative Diseases

GlobeNewswire November 6, 2019

AC Immune to Host Key Opinion Leader Event: 'Untangling' Tau Pathology to Treat Alzheimer's and Neurodegenerative Diseases

GlobeNewswire October 24, 2019

AC Immune Receives First Milestone Payment from Lilly in Small Molecule Tau Morphomer(TM) Program

GlobeNewswire September 20, 2019

AC Immune Awarded Michael J. Fox Foundation Grant to Accelerate Development of Parkinson's Disease Diagnostic Imaging Agent

GlobeNewswire September 4, 2019

AC Immune Reports Q2 2019 Financial Results, Business and Clinical Update

GlobeNewswire August 14, 2019

AC Immune Announces Research Collaboration with University of Pennsylvania Focusing on Pathogenic Protein TDP-43 in Neurodegenerative Diseases

GlobeNewswire August 12, 2019

AC Immune Initiates Ph1b/2a Study of Anti-Phospho-Tau Vaccine in Alzheimer's Disease

GlobeNewswire August 1, 2019

AC Immune Initiates Phase 1 Study of ACI-3024 Small Molecule Tau Morphomer(TM), an Investigational Treatment for Alzheimer's Disease

GlobeNewswire July 17, 2019

AC Immune Hosts KOL Event and Reports Initial Interim Clinical Data for ACI-24 Vaccine to Treat Alzheimer's Disease-like Symptoms in Subjects with Down Syndrome

GlobeNewswire July 11, 2019

AC Immune Announces Election of New Chairman of the Board at Annual General Meeting

GlobeNewswire June 28, 2019

AC Immune to Host Key Opinion Leader Meeting on Treating Alzheimer's in Down Syndrome

GlobeNewswire June 27, 2019

AC Immune Reports Initiation of a Phase 2 Substudy to Increase Understanding of Disease Progression in Familial Alzheimer's Disease

GlobeNewswire June 20, 2019

AC Immune Reports Q1 2019 Financial Results and Business Update

GlobeNewswire May 15, 2019

AC Immune to Present at the H.C. Wainwright Global Life Sciences Conference

GlobeNewswire April 1, 2019

AC Immune to Report Progress of Early-Stage Pipeline at AD/PD™ Congress

GlobeNewswire March 4, 2019